Navigation Links
Angioplasty No Better Than Drug Treatment in Long Run

Benefit disappears within three years, study finds

WEDNESDAY, Aug. 13 (HealthDay News) -- There are some advantages to artery-opening angioplasty over drug treatment for people with heart disease, but those advantages disappear within three years, according to the latest report on a pivotal study on the subject.

Angioplasty does offer a higher quality of life for months to a couple of years, said study leader Dr. William S. Weintraub, chief of cardiology at the Christiana Health Care System in Delaware.

In the COURAGE trial, the researchers tested angioplasty, with stent implants, against drug treatment for 2,287 people with stable coronary disease. Earlier analysis found improved quality of life for those having the artery-opening procedure that is formally called percutaneous coronary intervention (PCI). The latest report, in the Aug. 14 issue of the New England Journal of Medicine, found that by 36 months, there was no significant difference in health status between the two treatment groups.

"What one can say is that for people with chronic, stable coronary disease, PCI can be deferred," Weintraub said. "They can continue on medication aimed at their specific risk factors -- hypertension, lipid disorders, diabetes -- and should be encouraged to have a good lifestyle, with exercise, smoking cessation and weight control."

A decision to have PCI can depend on how an individual feels, Weintraub said. "If people say, 'My pain is so bad I can't function,' that is one thing," he said. "If people say, 'I have angina, but I'm doing OK,' that's another."

Angina is the chest pain that is a chief symptom of coronary disease.

Cost could be a factor in some decisions, Weintraub said. PCI is more expensive than drug therapy, but the current report does not mention money. An economic analysis of the COURAGE alternatives was expected to be published in September, Weintraub said.

However, a preliminary cost-benefit analysis presented by Weintraub last November found that "PCI adds about $10,000, without any significant gain in years of survival or quality of life." The cost of one year of life added by PCI varies from $150,000 to $300,000, the analysis found.

The cost of PCI versus drug treatment must be considered "by society as a whole," he said. "But when a doctor talks to a patient, the doctor is an advocate for that patient."

An individual's health insurance status can matter, Weintraub acknowledged. "Paying the cost out of pocket gives one a different point of view," he said.

The attitude of medical insurance providers does matter, said Dr. Eric D. Peterson, a professor of medicine at the Duke Clinical Research Institute. Insurance companies now are quite willing to pay for PCI, and "until that category is changed, the effect of this study will be modest," he said.

The COURAGE results show that PCI should not be the treatment of choice for people with stable heart disease, Peterson said.

"We have justified angioplasty for years by saying it is of great benefit to patients," he said. "This study shows no survival benefit and shows that the benefit in regard to symptom relief is temporary. Medical therapy should be considered for all patients with stable angina, unless they have severe pain when diagnosed."

The fact that 21 percent of those in the COURAGE trial who started on drug treatment eventually had PCI shows that a decision on surgery can safely be delayed, he said.

The hazards as well as the benefits of PCI should be considered when a decision is made, Peterson said. Of 1,000 persons undergoing PCI, two will die, 28 will have heart attacks related to the procedure, 60 to 90 will have improved symptom relief, and 800 will have no noticeable benefit above that given by drug treatment, his editorial said.

Another paper in the same issue of the journal reported a trial testing a new clot-preventing drug, bivalirudin, against heparin, the standard treatment, in PCI. The study of 4,570 persons having PCI found that bivalirudin did not provide a net clinical benefit, said a group headed by physicians in Germany.

More information

Angioplasty is explained by the U.S. National Heart, Lung, and Blood Institute.

SOURCES: William S. Weintraub, M.D., chief, cardiology, Christiana Health Care System, Newark, Del.; Eric D. Peterson, M.D., professor, medicine, Duke Clinical Research Unit, Durham, N.C.; Aug. 14, 2008, New England Journal of Medicine

Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Symposium at Angioplasty Summit TCT Asia Pacific 2008 Features OrbusNeichs Genous(TM) Bio-engineered R stent(TM)
2. Off-Hours Heart Patients Less Likely to Get Angioplasty
3. State Report Ranks LIJ as New Yorks Best Hospital for Angioplasty Survival
4. Angioplasty Proves Reasonable Alternative to Bypass Surgery
5. Anticoagulant Drugs Had Similar Outcomes After Angioplasty
6. Comparison of anticoagulants for angioplasty show similar outcomes
7. The Elderly Can Be Candidates for Angioplasty, Stenting
8. Doing Angioplasty Long After Heart Attack Still Worth It, Analysis Shows
9. Delayed angioplasty -- big bucks, no bang
10. Are women at greater risk from angioplasty?
11. Angioplasty Equals Bypass Surgery for Heart Patients: Study
Post Your Comments:
Related Image:
Angioplasty No Better Than Drug Treatment in Long Run
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of indulgence ... high can result in disappointment, perhaps even self-loathing. However, those who set the bar ... from reveals that behind the tendency to set low expectations is ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell ... pain and the benefits of holistic treatments, Serenity Recovery Center of Marne, ... Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Global law firm ... 2016 Legal Elite. The attorneys chosen by their peers for this recognition are considered ... Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal Elite ...
(Date:6/24/2016)... ... 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join ... wage raise to $12 an hour by 2020 and then adjusting it yearly to increase ... of the minimum wage, assure the wage floor does not erode again, and make future ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute ... Dr. Barry M. Weintraub as a prominent plastic surgeon and the network’s newest ... world, and the most handsome men, look naturally attractive. Plastic surgery should be ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016 Research and Markets has announced ... report to their offering. ... a favourable commercial environment for MedImmune to enter. The US ... will serve to drive considerable growth for effective anti-influenza medications. ... cap sales considerably, but development is still in its infancy. ...
(Date:6/23/2016)... and INDIANAPOLIS , June 23, ... a Lilly Diabetes Tomorrow,s Leaders Scholarship is any indication, ... winners, announced today online at by ... 1 diabetes stand in the way of academic and ... the Foundation,s scholarship program since 2012, and continues to ...
(Date:6/23/2016)... PRINCETON, N.J. , June 23, 2016  Guerbet ... of Premier Inc.,s Supplier Horizon Award . ... this year, Guerbet was recognized for its support of ... value creation through clinical excellence, and commitment to lower ... delighted to receive this recognition of our outstanding customer ...
Breaking Medicine Technology: